Univariate and multivariate analysis of factors influencing PFS and OS in the whole series and in the rituximab-treated group
| . | PFS (n = 183/127) . | OS (n = 193/136) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group and variable . | n . | % 5 y . | U . | M . | OR (95% CI) . | N . | % 5 y . | U . | M . | OR (95% CI) . |
| Whole series | ||||||||||
| HLA status | ||||||||||
| HLA-B*18 | 26 | 35 | .002 | .002 | 2.7 (1.4-4.9) | 103 | 53 | .0001 | .0004 | 4.4 (1.9-10.2) |
| Other HLA-B44 supertype alleles | 70 | 64 | NS | NS | — | 75 | 76 | .064 | .1 | 1.9 (0.9-4.2) |
| Other HLA alleles (reference) | 97 | 63 | — | — | — | 26 | 86 | — | — | — |
| Age-adjusted IPI | ||||||||||
| <2 | 78 | 70 | .064 | .057 | 1.7 (1.0-2.9) | 81 | 86 | .074 | .072 | 2.0 (0.9-4.3) |
| ≥2 | 125 | 60 | 132 | 77 | ||||||
| Rituximab group | ||||||||||
| HLA status | ||||||||||
| HLA-B*18 | 15 | 40 | .006 | .002 | 4.0 (1.7-9.6) | 15 | 60 | .0004 | .001 | 7.6 (2.2-26.7) |
| Other HLA-B44 supertype alleles | 47 | 59 | .09 | .052 | 2.0 (1.0-4.0) | 51 | 74 | .008 | .017 | 3.7 (1.3-11.0) |
| Other HLA alleles (reference) | 71 | 71 | — | — | — | 77 | 92 | — | — | — |
| Age-adjusted IPI | ||||||||||
| <2 | 57 | 78 | .018 | .006 | 2.7 (1.3-5.5) | 60 | 91 | .087 | .049 | 2.8 (1.0-7.7) |
| ≥2 | 80 | 60 | 86 | 81 | ||||||
| . | PFS (n = 183/127) . | OS (n = 193/136) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group and variable . | n . | % 5 y . | U . | M . | OR (95% CI) . | N . | % 5 y . | U . | M . | OR (95% CI) . |
| Whole series | ||||||||||
| HLA status | ||||||||||
| HLA-B*18 | 26 | 35 | .002 | .002 | 2.7 (1.4-4.9) | 103 | 53 | .0001 | .0004 | 4.4 (1.9-10.2) |
| Other HLA-B44 supertype alleles | 70 | 64 | NS | NS | — | 75 | 76 | .064 | .1 | 1.9 (0.9-4.2) |
| Other HLA alleles (reference) | 97 | 63 | — | — | — | 26 | 86 | — | — | — |
| Age-adjusted IPI | ||||||||||
| <2 | 78 | 70 | .064 | .057 | 1.7 (1.0-2.9) | 81 | 86 | .074 | .072 | 2.0 (0.9-4.3) |
| ≥2 | 125 | 60 | 132 | 77 | ||||||
| Rituximab group | ||||||||||
| HLA status | ||||||||||
| HLA-B*18 | 15 | 40 | .006 | .002 | 4.0 (1.7-9.6) | 15 | 60 | .0004 | .001 | 7.6 (2.2-26.7) |
| Other HLA-B44 supertype alleles | 47 | 59 | .09 | .052 | 2.0 (1.0-4.0) | 51 | 74 | .008 | .017 | 3.7 (1.3-11.0) |
| Other HLA alleles (reference) | 71 | 71 | — | — | — | 77 | 92 | — | — | — |
| Age-adjusted IPI | ||||||||||
| <2 | 57 | 78 | .018 | .006 | 2.7 (1.3-5.5) | 60 | 91 | .087 | .049 | 2.8 (1.0-7.7) |
| ≥2 | 80 | 60 | 86 | 81 | ||||||
Numbers in italics indicate P values >.05.
M, multivariate analysis; NS, not significant; U, univariate analysis.